A community-engaged randomized controlled trial of an integrative intervention with HIV-positive, methamphetamine-using men who have sex with men

Adam Carrico, Jennifer Jain, Michael V. Discepola, David Olem, Rick Andrews, William J. Woods, Torsten B. Neilands, Steven Shoptaw, Walter Gómez, Samantha E. Dilworth, Judith T. Moskowitz

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Contingency management (CM) is an evidence-based intervention providing tangible rewards as positive reinforcement for abstinence from stimulants such as methamphetamine. Integrative approaches targeting affect regulation could boost the effectiveness of CM in community-based settings and optimize HIV/AIDS prevention efforts. Methods/Design: This randomized controlled trial with HIV-positive, methamphetamine-using men who have sex with men (MSM) is examining the efficacy of a 5-session, individually delivered positive affect regulation intervention - Affect Regulation Treatment to Enhance Methamphetamine Intervention Success (ARTEMIS). ARTEMIS is designed to sensitize individuals to non-drug-related sources of reward as well as assist with managing depression and other symptoms of stimulant withdrawal during CM. HIV-positive, methamphetamine-using MSM who are enrolled in a community-based, 12-week CM program are randomized to receive ARTEMIS or an attention-matched control condition. Follow-up assessments are conducted at 3, 6, 12, and 15 months after enrollment in CM. Four peripheral venous blood samples are collected over the 15-month follow-up with specimen banking for planned biomarker sub-studies. The primary outcome is mean HIV viral load. Secondary outcomes include: sustained HIV viral suppression, T-helper cell count, psychological adjustment, stimulant use, and potentially amplified transmission risk behavior. Discussion: Implementation of this randomized controlled trial highlights the importance of delineating boundaries between research activities and community-based service provision. It also provides insights into best practices for integrating the distinct agendas of academic and community partners in clinical research. This trial is currently enrolling and data collection is anticipated to be completed in September of 2018. Trial registration: This trial was registered on clinicaltrials.gov (NCT01926184) on August 16, 2013.

Original languageEnglish (US)
Article number673
JournalBMC Public Health
Volume16
Issue number1
DOIs
StatePublished - Jul 30 2016

Fingerprint

Methamphetamine
Randomized Controlled Trials
HIV
Reward
Substance Withdrawal Syndrome
Social Welfare
Risk-Taking
Viral Load
Practice Guidelines
Research
Acquired Immunodeficiency Syndrome
Therapeutics
Cell Count
Biomarkers
Depression

Keywords

  • Contingency management
  • HIV/AIDS
  • Men who Have Sex with men
  • Methamphetamine
  • Positive affect
  • Resilience

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

A community-engaged randomized controlled trial of an integrative intervention with HIV-positive, methamphetamine-using men who have sex with men. / Carrico, Adam; Jain, Jennifer; Discepola, Michael V.; Olem, David; Andrews, Rick; Woods, William J.; Neilands, Torsten B.; Shoptaw, Steven; Gómez, Walter; Dilworth, Samantha E.; Moskowitz, Judith T.

In: BMC Public Health, Vol. 16, No. 1, 673, 30.07.2016.

Research output: Contribution to journalArticle

Carrico, A, Jain, J, Discepola, MV, Olem, D, Andrews, R, Woods, WJ, Neilands, TB, Shoptaw, S, Gómez, W, Dilworth, SE & Moskowitz, JT 2016, 'A community-engaged randomized controlled trial of an integrative intervention with HIV-positive, methamphetamine-using men who have sex with men', BMC Public Health, vol. 16, no. 1, 673. https://doi.org/10.1186/s12889-016-3325-1
Carrico, Adam ; Jain, Jennifer ; Discepola, Michael V. ; Olem, David ; Andrews, Rick ; Woods, William J. ; Neilands, Torsten B. ; Shoptaw, Steven ; Gómez, Walter ; Dilworth, Samantha E. ; Moskowitz, Judith T. / A community-engaged randomized controlled trial of an integrative intervention with HIV-positive, methamphetamine-using men who have sex with men. In: BMC Public Health. 2016 ; Vol. 16, No. 1.
@article{560bec8d009343c4a72f16c80b2be376,
title = "A community-engaged randomized controlled trial of an integrative intervention with HIV-positive, methamphetamine-using men who have sex with men",
abstract = "Background: Contingency management (CM) is an evidence-based intervention providing tangible rewards as positive reinforcement for abstinence from stimulants such as methamphetamine. Integrative approaches targeting affect regulation could boost the effectiveness of CM in community-based settings and optimize HIV/AIDS prevention efforts. Methods/Design: This randomized controlled trial with HIV-positive, methamphetamine-using men who have sex with men (MSM) is examining the efficacy of a 5-session, individually delivered positive affect regulation intervention - Affect Regulation Treatment to Enhance Methamphetamine Intervention Success (ARTEMIS). ARTEMIS is designed to sensitize individuals to non-drug-related sources of reward as well as assist with managing depression and other symptoms of stimulant withdrawal during CM. HIV-positive, methamphetamine-using MSM who are enrolled in a community-based, 12-week CM program are randomized to receive ARTEMIS or an attention-matched control condition. Follow-up assessments are conducted at 3, 6, 12, and 15 months after enrollment in CM. Four peripheral venous blood samples are collected over the 15-month follow-up with specimen banking for planned biomarker sub-studies. The primary outcome is mean HIV viral load. Secondary outcomes include: sustained HIV viral suppression, T-helper cell count, psychological adjustment, stimulant use, and potentially amplified transmission risk behavior. Discussion: Implementation of this randomized controlled trial highlights the importance of delineating boundaries between research activities and community-based service provision. It also provides insights into best practices for integrating the distinct agendas of academic and community partners in clinical research. This trial is currently enrolling and data collection is anticipated to be completed in September of 2018. Trial registration: This trial was registered on clinicaltrials.gov (NCT01926184) on August 16, 2013.",
keywords = "Contingency management, HIV/AIDS, Men who Have Sex with men, Methamphetamine, Positive affect, Resilience",
author = "Adam Carrico and Jennifer Jain and Discepola, {Michael V.} and David Olem and Rick Andrews and Woods, {William J.} and Neilands, {Torsten B.} and Steven Shoptaw and Walter G{\'o}mez and Dilworth, {Samantha E.} and Moskowitz, {Judith T.}",
year = "2016",
month = "7",
day = "30",
doi = "10.1186/s12889-016-3325-1",
language = "English (US)",
volume = "16",
journal = "BMC Public Health",
issn = "1471-2458",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - A community-engaged randomized controlled trial of an integrative intervention with HIV-positive, methamphetamine-using men who have sex with men

AU - Carrico, Adam

AU - Jain, Jennifer

AU - Discepola, Michael V.

AU - Olem, David

AU - Andrews, Rick

AU - Woods, William J.

AU - Neilands, Torsten B.

AU - Shoptaw, Steven

AU - Gómez, Walter

AU - Dilworth, Samantha E.

AU - Moskowitz, Judith T.

PY - 2016/7/30

Y1 - 2016/7/30

N2 - Background: Contingency management (CM) is an evidence-based intervention providing tangible rewards as positive reinforcement for abstinence from stimulants such as methamphetamine. Integrative approaches targeting affect regulation could boost the effectiveness of CM in community-based settings and optimize HIV/AIDS prevention efforts. Methods/Design: This randomized controlled trial with HIV-positive, methamphetamine-using men who have sex with men (MSM) is examining the efficacy of a 5-session, individually delivered positive affect regulation intervention - Affect Regulation Treatment to Enhance Methamphetamine Intervention Success (ARTEMIS). ARTEMIS is designed to sensitize individuals to non-drug-related sources of reward as well as assist with managing depression and other symptoms of stimulant withdrawal during CM. HIV-positive, methamphetamine-using MSM who are enrolled in a community-based, 12-week CM program are randomized to receive ARTEMIS or an attention-matched control condition. Follow-up assessments are conducted at 3, 6, 12, and 15 months after enrollment in CM. Four peripheral venous blood samples are collected over the 15-month follow-up with specimen banking for planned biomarker sub-studies. The primary outcome is mean HIV viral load. Secondary outcomes include: sustained HIV viral suppression, T-helper cell count, psychological adjustment, stimulant use, and potentially amplified transmission risk behavior. Discussion: Implementation of this randomized controlled trial highlights the importance of delineating boundaries between research activities and community-based service provision. It also provides insights into best practices for integrating the distinct agendas of academic and community partners in clinical research. This trial is currently enrolling and data collection is anticipated to be completed in September of 2018. Trial registration: This trial was registered on clinicaltrials.gov (NCT01926184) on August 16, 2013.

AB - Background: Contingency management (CM) is an evidence-based intervention providing tangible rewards as positive reinforcement for abstinence from stimulants such as methamphetamine. Integrative approaches targeting affect regulation could boost the effectiveness of CM in community-based settings and optimize HIV/AIDS prevention efforts. Methods/Design: This randomized controlled trial with HIV-positive, methamphetamine-using men who have sex with men (MSM) is examining the efficacy of a 5-session, individually delivered positive affect regulation intervention - Affect Regulation Treatment to Enhance Methamphetamine Intervention Success (ARTEMIS). ARTEMIS is designed to sensitize individuals to non-drug-related sources of reward as well as assist with managing depression and other symptoms of stimulant withdrawal during CM. HIV-positive, methamphetamine-using MSM who are enrolled in a community-based, 12-week CM program are randomized to receive ARTEMIS or an attention-matched control condition. Follow-up assessments are conducted at 3, 6, 12, and 15 months after enrollment in CM. Four peripheral venous blood samples are collected over the 15-month follow-up with specimen banking for planned biomarker sub-studies. The primary outcome is mean HIV viral load. Secondary outcomes include: sustained HIV viral suppression, T-helper cell count, psychological adjustment, stimulant use, and potentially amplified transmission risk behavior. Discussion: Implementation of this randomized controlled trial highlights the importance of delineating boundaries between research activities and community-based service provision. It also provides insights into best practices for integrating the distinct agendas of academic and community partners in clinical research. This trial is currently enrolling and data collection is anticipated to be completed in September of 2018. Trial registration: This trial was registered on clinicaltrials.gov (NCT01926184) on August 16, 2013.

KW - Contingency management

KW - HIV/AIDS

KW - Men who Have Sex with men

KW - Methamphetamine

KW - Positive affect

KW - Resilience

UR - http://www.scopus.com/inward/record.url?scp=84979743512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979743512&partnerID=8YFLogxK

U2 - 10.1186/s12889-016-3325-1

DO - 10.1186/s12889-016-3325-1

M3 - Article

VL - 16

JO - BMC Public Health

JF - BMC Public Health

SN - 1471-2458

IS - 1

M1 - 673

ER -